This article is more than 5 years old. Information may no longer be current.

Ozurdex approved in EU for treatment of DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press release.

Under the marketing authorization extension, the dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who were unable to undergo noncorticosteroid therapy, according to the press release.

The implant is already indicated for the treatment of macular edema following branch retinal vein occlusion and central retinal vein occlusion, as well as for the treatment of noninfectious uveitis, according to the press release. It was approved by the U.S. Food and Drug Administration on June 30.